Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

he first quarter of 2011. Study 012 will be an 18-month, randomized, open-label study comparing migalastat HCl to enzyme replacement therapy (ERT) in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

About Fabry Disease

Fabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A). The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke.

It is currently estimated that Fabry disease affects approximately 5,000 to 10,000 people worldwide.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products and the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products. Words such as, but not limited to, "look forward to," "believe," "expect," "anticip
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... has announced today that they have received CE ... Device. Velox CD™ provides a safe and predictable ... procedures. The single size velox CD™ is indicated ... 5F to 8F.  Velox CD™ utilizes ...
(Date:7/30/2014)... , July 30, 2014 Reportlinker.com announces ... in its catalogue: mHealth and Home ... http://www.reportlinker.com/p0356852/mHealth-and-Home-Monitoring-–-6th-Edition.html Executive summary ... leading to better outcomes, decreased costs and improved ... mHealth solutions is still in an early stage, ...
(Date:7/30/2014)... --  Unique Pizza and Subs Corporation ("Unique," ... Delaware Corporation, is pleased to announce it has ... ("Larasan"), a nature-based pharmaceutical company that produces and distributes ... will work with Unique to help distribute its ... distribution network throughout China ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3
... YORK, Oct. 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ... clinical-stage pipeline, and multiple licenses with major pharmaceutical companies ... interview with Dr. Daniel Chain, Ph.D., Chairman and CEO ... Dr. Chain will be discussing the state ...
... Health Solutions, Inc. (NYSE: MHS ) today ... the Silver Award for Best Practices in Health Care ... healthcare accreditation organization, during the URAC 12th Annual Quality ... ) Medco,s program was selected as one ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2Medco Wins 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:7/30/2014)... 2014 Visitors to our region recognize ... to ensure its protection. Bob Kiesendahl, one of the ... the Delaware Highlands Conservancy for donations collected through participation ... donations add up fast, as visitors welcome the opportunity ... River Region. , The Kiesendahl family has owned Woodloch ...
(Date:7/30/2014)... "we caught it early" is possibly the best news ... cancer diagnosis. Combating cancer in its earliest stages, when ... the body, gives patients the best chances of survival. ... other forms of cancer are touted for saving lives ... screenings as a precautionary measure, especially for high-risk patients. ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people with diverticulitis and confirmed that many suffer psychological and physical symptoms long after their ... UCLA team led by Dr. Brennan Spiegel interviewed patients in great detail about the symptoms they experience weeks, months or even years ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Over 630 ... Pinhole Surgical Technique®, the revolutionary minimally invasive treatment for ... considered by many of his peers to be the ... speaker at a recent Chao Pinhole Surgical Technique® training ... Dr. Shanelec is the recipient of the American Academy ...
(Date:7/30/2014)... 2014 The American Telemedicine Association ... Thad Cochran (R-MS) and Roger Wicker (R-MS) for ... coverage under Medicare, Medicaid and Federal Communications Commission ... Republicans, introduced the Telehealth Enhancement Act as S. ... H.R. 3306, introduced by Rep. Gregg Harper (R-MS) ...
Breaking Medicine News(10 mins):Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:ATA Applauds Senators’ Push for Federal Telemedicine Improvements 2
... the first to use a new tool to identify the ... of what these microscopic signatures or biomarkers should look like. ... Journal of Proteome Research, the advance could one day lead ... cancer as well as other diseases. , With many diseases, ...
... Provides Interventional Cardiologists with Enhanced ... Faster, More Precise Procedures, CHICAGO, March 31 According ... 1 killer,with an average of one death every 37 seconds. ... contributed to the surge of,Americans with cardiac issues. To address ...
... on Blue Cross ... EAGAN, Minn., March 31 In a peer-reviewed ... Cross and Blue,Shield of Minnesota (Blue Cross) reports that ... visits to the emergency room and,had an 11 percent ...
... medication, study finds , , MONDAY, March 31 (HealthDay News) ... diabetes drug, Amaryl, at slowing clogging of the arteries ... disease. , The Cleveland Clinic researchers behind the new ... diabetes medication has been shown to slow atherosclerosis, giving ...
... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
... Considered by many in medical,marketing to be ... Ferdinand has joined,prominent Houston healthcare and sports marketing ... and Business Development., In her new role ... counsel for existing clients, and develop relationships,with potential ...
Cached Medicine News:Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 4Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:Diabetes Drug Slows Clogging of Arteries 2Health News:Diabetes Drug Slows Clogging of Arteries 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: